The account--elilillyco--has posted old photographs of Lilly's facilities and researchers alongside pictures of what its current staff are doing.
Over the past decade a plethora of digital formats have begun competing with print, television, radio and conferences for biopharma marketeers' budgets. And while initial uptake was slow, a survey has now found Big Data, social media and mobile have doubled their share of the marketing mix since 2012.
Which pharma companies are getting it right when it comes to social media? As far as Twitter is concerned, Boehringer Ingelheim is up there.
Biopharma has encountered more critics than cheerleaders as it has cautiously edged into social media, but Boehringer Ingelheim has recently won a high-profile supporter: Twitter. In a case study, the social network praised Boehringer's use of its platform.
Inherent conservatism and a lack of regulatory guidance have caused pharma to edge slowly onto social media platforms. Yet patients still talk about their health online. Should drugmakers be listening?
It's no revelation that pharma is behind the curve when it comes to social media. Consider yourselves fortunate, then, that the IMS Institute for Healthcare Informatics chose to delve into the subject. Its new report makes the case for social media--complete with the sort of statistics you'd want for your own memos to the powers that be.
Forget a unified theory of social media from the FDA. It's going to be more of a puzzle-piece approach. As Regulatory Focus reports, the FDA plans to issue several more sets of rules for pharma companies using Twitter, Facebook, Pinterest, et al.
Do people listen to the FDA? The agency wants to know--and it's planning to track online chatter to find out.
When Pfizer came to set up its Twitter account in 2009, the social network was already a big deal, with users sending 100,000 tweets per hour when Michael Jackson died. Arriving late to the party meant the @Pfizer handle was already taken. Now, four years later, Pfizer has finally claimed the account.
Life science vendors face a balancing act when using social media. Giving users the hard sell will bring rejection and reflect badly on the company, but a softly-softly plan might not be noticed at all. Fortunately for vendors, a survey suggests scientists are increasingly accepting of companies on Facebook and Twitter.